The role of B cells in multiple sclerosis: Current and future therapies

Austin Negron, Rachel R. Robinson, Olaf Stuve, Thomas G. Forsthuber

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab (RTX), a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated: B cells. This has been reaffirmed by results from clinical trials testing the efficacy of subsequently developed B cell-depleting mAbs targeting CD20 as well as studies revisiting the effects of previous disease-modifying therapies (DMTs) on B cell subsets thought to modulate disease severity. In this review, we summarize current knowledge regarding the complex roles of B cells in MS pathogenesis and current and potential future B cell-directed therapies.

Original languageEnglish (US)
Pages (from-to)10-23
Number of pages14
JournalCellular Immunology
StatePublished - May 2019

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'The role of B cells in multiple sclerosis: Current and future therapies'. Together they form a unique fingerprint.

Cite this